FDA Ranks DNA Cancer Detector as Safe Tool
Published Date: 5/9/2025
Rule
Summary
The FDA is officially putting the DNA test that checks for tiny amounts of blood cancer back into a safer, more controlled category called Class II. This means the test will have special rules to make sure it works well and is safe, helping patients get better access to this cool technology faster. Companies making these tests should get ready for these new rules, which aim to keep things safe without slowing down innovation.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Patients: Easier access to MRD DNA test
The FDA has classified the DNA-based test that measures minimal residual disease in hematological malignancies as Class II (special controls). The FDA says this classification will provide reasonable assurance of safety and effectiveness and will enhance patients' access by reducing regulatory burdens.
Manufacturers: Subject to Class II special controls
Companies that make the DNA-based minimal residual disease test must follow the Class II special controls identified in this FDA order. The rule says the special controls will be part of the codified classification and asks companies to prepare for the new regulatory requirements while noting the action reduces regulatory burdens.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Previous / Next Documents
Previous: 2025-08137, New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA is updating rules about new animal medicines based on recent approvals and changes from early 2025. These updates affect drug makers and pet owners by making the rules clearer and reflecting the latest drug approvals and withdrawals. This means safer, better-regulated animal medicines are on the way, with no surprise costs or delays.
Next: 2025-08144, Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Measure Non-Microbial Analytes To Aid in the Detection and Identification of Localized Human Infections
The FDA is officially putting devices that detect and measure non-microbial signs of localized infections into a special safety category called Class II. This change helps make sure these devices are safe and work well, while also making it easier for patients to get new, helpful tools faster. Companies making these devices will now follow clear rules, which should speed up innovation without extra costs or delays.